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Hepatitis E virus (HEV) is an important human pathogen, although little is known about its biology and
replication. Comparative sequence analysis revealed a hypervariable region (HVR) with extensive sequence
variations in open reading frame 1 of HEV. To elucidate the role of the HVR in HEV replication, we first
constructed two HVR deletion mutants, hHVRd1 and hHVRd2, with in-frame deletion of amino acids (aa) 711
to 777 and 747 to 761 in the HVR of a genotype 1 human HEV replicon. Evidence of HEV replication was
detected in Huh7 cells transfected with RNA transcripts from mutant hHVRd2, as evidenced by expression of
enhanced green fluorescent protein. To confirm the in vitro results, we constructed three avian HEV mutants
with various HVR deletions: mutants aHVRd1, with deletion of aa 557 to 585 (557-585); aHVRd2 (612-641);
and aHVRd3 (557-641). Chickens intrahepatically inoculated with capped RNA transcripts from mutants
aHVRd1 and aHVRd2 developed active viral infection, as evidenced by seroconversion, viremia, and fecal virus
shedding, although mutant aHVRd3, with complete HVR deletion, was apparently attenuated in chickens. To
further verify the results, we constructed four additional HVR deletion mutants using the genotype 3 swine
HEV as the backbone. Mutants sHVRd2 (722-781), sHVRd3 (735-765), and sHVRd4 (712-765) were shown
to tolerate deletions and were infectious in pigs intrahepatically inoculated with capped RNA transcripts from
the mutants, whereas mutant sHVRd1 (712-790), with a nearly complete HVR deletion, exhibited an atten-
uation phenotype in infected pigs. The data from these studies indicate that deletions in HVR do not abolish
HEV infectivity in vitro or in vivo, although evidence for attenuation was observed for HEV mutants with a
larger or nearly complete HVR deletion.
Hepatitis E virus (HEV), the causative agent of human
hepatitis E, is a nonenveloped, single-stranded, positive-sense
RNA virus in the genus Hepevirus of the family Hepeviridae (9).
Hepatitis E is an important public health disease in many
developing countries and is also endemic in some industrial-
ized countries (1, 2, 4, 8, 19, 41). HEV transmission occurs
primarily by the fecal-oral route through contaminated drink-
ing water or water supplies in areas with poor sanitation (35).
The disease mainly affects young adults, and the mortality rate
is generally less than 1%, but it can reach up to 28% among
infected pregnant women (17, 28). A relatively high prevalence
of anti-HEV antibodies in healthy individuals has been re-
ported in the United States and other industrialized countries
where HEV infections are only sporadic (33, 34, 51). HEV
antibodies have also been detected in several other animal
species, including rodents, pigs, and chickens (12, 30, 35, 54).
In 1997, the first animal strain of HEV, swine HEV, was
discovered and characterized from pigs in the United States
(38). More recently, another strain of HEV, avian HEV, from
chickens with hepatitis-splenomegaly syndrome was discovered
and characterized in the United States (18). The discovery of
animal strains of HEV and the existence of a population of
individuals in industrialized countries who are seropositive for
HEV have led to a hypothesis that animal reservoirs exist for
HEV (34). Increasing evidence indicates that hepatitis E is
indeed a zoonotic disease (35, 39) and that pigs (and perhaps
other species) are animal reservoirs for HEV (34).
There are at least four major genotypes of HEV: genotype 1
(primarily Burmese-like Asian strains) (3, 50, 52); genotype 2
(a single Mexican strain) (21); genotype 3 (strains from rare
endemic cases in industrialized countries, including the United
States, Europe, and Japan, and swine HEV strains from pigs
worldwide) (11, 38, 45–48); and genotype 4 (variant strains
from endemic cases in Asia and swine HEV strains from pigs
in Asia) (49, 57). All swine HEV strains identified thus far
worldwide belong to either genotype 3 or 4 (20, 22, 40, 47). The
avian HEV from chickens likely represents a new genus in the
family Hepeviridae (25).
The genome of HEV is approximately 7.2 kb in length and
consists of three open reading frames (ORFs) (14, 31, 43, 50,
55) and short 5 and 3 noncoding regions (NCR), followed by
a poly(A) tail (8, 15, 29, 50). The ORF1 encodes a nonstruc-
tural polyprotein, which contains putative functional motifs
characteristic of methyltransferase, protease, helicase, and
RNA-dependent RNA polymerase (31, 42). ORF2 encodes
the capsid protein of about 660 amino acids (aa). The small
ORF3 encodes a phosphoprotein of about 123 aa, the biolog-
ical function of which has yet to be fully defined (14, 15, 31, 50,
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55, 58, 60). Though ORF1 is essential for HEV replication, it
contains a highly heterogeneous and hypervariable region
(HVR) among HEV strains (25, 32, 44, 53). The size differ-
ences among different HEV genomes are confined mainly to
the HVR of ORF1 (25). The observed extensive inter- and
intragenotypic sequence variations in the HVRs of HEV ge-
nomes suggest that the HVR may not be necessary for virus
replication. However, sequences not required for virus infec-
tivity or spread are normally rapidly lost in vivo, especially in
small RNA viruses like HEV. Therefore, the fact that HEV
does retain such a hypervariable sequence in its genome
suggested a potential biological role for the HVR in HEV
replication and/or pathogenesis, which warranted further
investigation.
Reverse genetic systems for HEV have been recently estab-
lished, permitting the manipulation of the HEV genome to
explore the potential functions of viral genes (10, 24, 26). To
elucidate the potential role of the HVR in HEV replication
and/or pathogenesis, in this study we constructed various HVR
deletion mutants using a genotype 1 human HEV replicon, an
avian HEV infectious clone, and genotype 3 swine HEV in-
fectious clones. The mutants were tested for infectivity in
Huh7 liver cells, as well as in chickens and pigs. The results
from this study indicate that deletions of HVR from the HEV
genome do not affect virus viability in vitro or in vivo, although
virus mutants with a larger or nearly complete HVR deletion
were apparently attenuated in infected animals.
MATERIALS AND METHODS
Cells and infectious cDNA clones. The genotype 1 human HEV (Sar55 strain)
infectious clone (10) and a subclone of the Huh7 liver cell line (7, 15) were gifts
from Suzanne Emerson and Robert Purcell at the Laboratory of Infectious
Diseases, National Institute of Allergy and Infectious Diseases, NIH. The infec-
tious cDNA clones of the genotype 3 swine HEV (26) and avian HEV (24) were
reported previously.
Sequence analysis of the HVR among known HEV strains. In order to identify
the length of the HVR and to determine the intragenotypic and intergenotypic
sequence identities in the HVR among different HEV strains of the four major
genotypes, the amino acid sequences flanking the HVR among known mamma-
lian strains of HEV (Fig. 1) and the corresponding region of avian HEV were
aligned and analyzed using the Clustal W method of the MegAlign program
(DNAStar, Inc.). The putative HVR for each genotype of mammalian HEV and
the corresponding HVR in avian HEV were predicted on the basis of the
sequence alignment.
Construction of genotype 1 human HEV HVR deletion mutant replicons. The
enhanced green fluorescent protein (EGFP)-expressing HEV replicon was con-
structed in our laboratory (Y. W. Huang and X. J. Meng, unpublished data) using
the infectious cDNA clone of genotype 1 human HEV (strain Sar55), pSK-
HEV-2 (10), as the backbone. Briefly, the 5 NCR, ORF1, and 3 NCR in this
EGFP replicon are intact, with part of the carboxy terminus of ORF2 fused to
the EGFP gene. The amino terminus of the ORF2 gene (nt 5148 to 5816)
downstream of the first methionine was removed, and the EGFP gene was
inserted in frame with the ORF2 initiation codon. The EGFP replicon was shown
to express the EGFP protein when transfected into Huh7 liver cells (Huang and
Meng, unpublished).
Two HVR deletion mutants of the genotype 1 HEV replicon were constructed
using fusion PCR (Fig. 2). Amino acid residues 711 to 777 and 747 to 761,
corresponding to nucleotides (nt) 2131 to 2331 and 2239 to 2283, were deleted
to construct the HVR deletion mutants hHVRd1 and hHVR2, respectively. The
two fragments used for fusion PCR were first amplified with the primer sets Hu
F/Hu r1 and Hu f1/Hu R for the mutant hHVRd1 and Hu F/Hu r2 and Hu f2/Hu
R for the mutant hHVRd2 (Table 1). The PCR products amplified from each
mutant were then used in the fusion PCR with primer set Hu F/Hu R (Table 1).
To produce the two HVR deletion mutants, the fusion product was purified,
digested with SphI and NsiI, and ligated into the backbone of the genotype 1
HEV EGFP replicon from which the SphI-NsiI region had been deleted.
Construction of avian HEV HVR deletion mutants using the avian HEV
infectious cDNA clone as the backbone. To further elucidate the role of the HVR
in HEV replication, we utilized the genetically distinct avian HEV to produce
three avian HEV HVR deletion mutants. Avian HEV shares only approximately
50% nucleotide sequence identity with the mammalian HEV strains (23–25),
although avian HEV and mammalian HEV have similar genomic organizations.
Since the complete sequences of avian HEV are available for only two strains,
the putative HVR in avian HEV is derived from the corresponding HVR in
mammalian HEV.
To construct the three avian HEV HVR deletion mutants with various lengths,
the avian infectious cDNA clone (24), pT7-aHEV, was used as the backbone
(Fig. 3). Mutant aHVRd1 was created by PCR to delete amino acid residues 557
to 585 (nt 1693 to 1779) using the primers Avf and AvR (Table 1). Similarly, to
construct mutant aHVRd2, primers AvF and Avr were used to delete amino acid
residues 612 to 641 (nt 1858 to 1947). All four primers contain a unique HpaI
restriction site. The PCR products were purified with a GeneClean II kit, di-
gested with HpaI, and ligated into the backbone of the avian HEV infectious
clone pT7-aHEV from which the HpaI region had been deleted. For the con-
struction of mutant aHVRd3, aa 557 to 641 (nt 1693 to 1947) were deleted by
FIG. 1. Schematic diagram showing the relative positions of the HVR of ORF1 from representative isolates in four major genotypes of
mammalian HEV (genotypes 1 to 4, in parentheses), along with putative functional domains: MET, methyltransferase; P, papain-like cysteine
protease; Y, Y domain; H, HVR; X, X domain; HEL, helicase; RDRP, RNA-dependent RNA polymerase. The amino acid sequences of different
HEV strains were aligned using the Clustal W method of the MegAlign program (DNAStar, Inc.). The amino acid sequence in the HVR of the
genotype 1 Sar55 human HEV strain is shown at the top, and only differences are indicated for the other strains. Amino acid sequences identical
to the genotype 1 HEV Sar55 sequence are indicated by dots, and deletions are indicated by dashes. Representative strains from each genotype
used in this study are underlined.
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direct digestion of the avian HEV infectious cDNA clone with HpaI and religa-
tion of the ends after purification.
Construction of swine HEV HVR deletion mutants using the genotype 3 swine
HEV infectious cDNA clone as the backbone. To more definitively verify the role
of the HVR in HEV replication, we subsequently constructed four additional
HVR deletion mutants with a different genotype, the genotype 3 swine HEV.
Briefly, the infectious cDNA clone pSHEV-3 of the prototype genotype 3 swine
HEV (26) was used as the backbone for the construction of four HVR deletion
mutants using fusion PCR. Amino acid residues 712 to 790, 722 to 781, 735 to
765, and 712 to 765 (corresponding to nt 2160 to 2396, 2190 to 2369, 2229 to
2321, and 2160 to 2321, respectively) were deleted from the infectious cDNA
clone pSHEV-3 to produce HVR deletion mutants sHVRd1, sHVRd2, sHVRd3,
and sHVRd4, respectively (Fig. 4). The two fragments used for fusion PCR were
first amplified with the primer sets Sw F/Sw r1 and Sw f1/Sw R for the mutant
sHVRd1, Sw F/Sw r2 and Sw f2/Sw R for the mutant sHVRd2, Sw F/Sw r3 and
Sw f3/Sw R for the mutant sHVRd3, and Sw F/Sw r1 and Sw f4/Sw R for the
FIG. 2. (A) Schematic diagram showing the HVR (aa 707 to 777) in ORF1 of the genotype 1 human HEV (strain Sar55) replicon expressing
EGFP. MET, methyltransferase; P, papain-like cysteine protease; Y, Y domain; H, HVR; X, X domain; HEL, helicase; RDRP, RNA-dependent
RNA polymerase. The amino acid sequence of each HVR deletion mutant is aligned with that of the wild-type Sar55 HEV replicon to show the
relative positions of the in-frame amino acid deletions: mutants hHVRd1 (aa 711 to 777) and hHVRd2 (aa 747 to 761). (B) Fluorescence
microscopy of Huh7 liver cells at 6 days posttransfection with similar amounts of capped RNA transcripts from the wild-type Sar55 replicon with
the EGFP gene (A), HVR deletion mutants hHVRd1 (B) and hHVRd2 (C), and mock-transfected cells (D).
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mutant sHVRd4 (Table 1). PCR products amplified from each mutant were then
used in the fusion PCR with primer set Sw F/Sw R (Table 1). The fusion PCR
products were purified, digested with XhoI and SexAI, and ligated into the
backbone of the genotype 3 swine HEV infectious cDNA clone pSHEV-3 from
which the XhoI-SexAI region had been deleted.
In vitro transcription. For demonstration of the viability of the HVR deletion
mutants in Huh7 liver cells, the genotype 1 human HEV EGFP replicon and its
derived HVR deletion mutants (hHVRd1 and hHVRd2) were first linearized
with BglII and purified by phenol-chloroform extraction and ethanol precipi-
tation. Capped RNA transcripts were synthesized with the mMESSAGE
mMACHINE T7 kit (Ambion) from the mutant and wild-type replicons (24).
Briefly, each transcription reaction was performed in a 20-l reaction mixture
containing 1 g linearized cDNA template, 2 l 10 reaction buffer, 10 l 2
nucleoside triphosphate/Cap, 2 l enzyme mixture, and an additional 1 l 30 mM
GTP stock for capping. The mixtures were incubated at 37°C for 1.5 h, and 0.5
l of each reaction mixture was run on a 0.8% agarose gel to check the quality
of the RNA transcripts. Each transcription mixture was cooled on ice and used
for the transfection of Huh7 liver cells as previously described (7).
For avian HEV mutants, the full-length cDNA clone of avian HEV and the
three avian HEV HVR deletion mutants were linearized by digestion with XhoI
and purified by phenol-chloroform extraction. Each in vitro transcription reac-
tion was performed in a 300-l reaction as described previously (24) to generate
capped full-length RNA transcripts. RNA transcripts from each cDNA clone
were diluted 1:4 with cold RNase-, DNase-, and proteinase-free phosphate-
buffered saline (PBS) buffer, frozen on dry ice, and used for intrahepatic inoc-
ulation of chickens on the same day.
For the genotype 3 swine HEV mutants, the full-length cDNA clone of swine
HEV and the four HVR deletion mutants were linearized with XbaI and puri-
fied. Capped RNA transcripts were synthesized from each cDNA clone in a
600-l reaction as described previously (27). Once the RNA transcripts were
examined for quality on an agarose gel, the transcription reaction mixture from
each clone was diluted with 4 volumes of cold RNase-, DNase-, and proteinase-
free PBS buffer; aliquoted into 1-ml vials; and immediately frozen on dry ice until
it was used for intrahepatic inoculation of pigs the next day.
In vitro transfection of Huh7 liver cells with genotype 1 human HEV HVR
deletion mutant replicons. The Huh7 cells grown in a six-well plate were washed
once with serum-free medium prior to transfection. Five microliters of the
capped RNA transcripts generated from the wild type or HVR deletion mutants
of the genotype 1 HEV EGFP replicon were mixed with l ml of Opti-MEM
(Invitrogen) containing 10 l of DMRIE-C (Invitrogen), and the mixture was
overlaid on cells in a drained well. After 4 h of incubation at 34.5°C, the mixture
was aspirated, fresh Dulbecco’s modified Eagle’s medium containing 10% fetal
bovine serum was added, and the cultures were continuously incubated at 34.5°C.
Expression of EGFP in transfected cells was examined on days 4, 5, and 6
posttransfection with a fluorescence microscope (Nikon).
Evaluation of the infectivity of avian HEV HVR deletion mutants in specific-
pathogen-free (SPF) chickens. The lack of an efficient cell culture system for
HEV propagation limited our ability to test the viability and infectivity of mutant
or wild-type viruses in cell cultures. We had previously developed a unique
procedure (intrahepatic inoculation of chickens with capped RNA transcripts
from avian HEV infectious clones via percutaneous injection) to successfully
determine the infectivity of avian HEV cDNA clones (24). Therefore, to test the
infectivity and replication competency of the avian HEV HVR deletion mutants,
we utilized the percutaneous-injection procedure for intrahepatic inoculation of
chickens with capped RNA transcripts from the wild-type avian HEV infectious
clone and HVR deletion mutants as described previously (24).
Briefly, 15 11-week-old SPF chickens that were negative for avian HEV RNA
and antibodies were divided into five groups (groups A through E), with 3
chickens in each group (Fig. 3). The RNA transcripts were injected immediately,
after a quick thaw, into four different sites in each liver, with approximately 100
l per injection site. Three chickens in group A (5357, 5361, and 5368) were each
injected with 400 l of RNA transcripts from mutant aHVRd1; chickens 5353,
5372, and 5388 in group B with RNA transcripts from mutant clone aHVRd2;
and chickens 5354, 5355, and 5385 in group C with RNA transcripts from mutant
aHVRd3. Chickens 5362, 5367, and 5374 in group D were each injected with
RNA transcripts from the wild-type avian HEV infectious clone and served as
positive controls. The three chickens in group E (5352, 5358, and 5369) were
injected similarly with PBS buffer as negative controls (Fig. 3). Fecal swabs and
sera were collected from each inoculated chicken at weekly intervals and tested
by RT-PCR for avian HEV RNA. Weekly serum samples were also tested by
enzyme-linked immunosorbent assay (ELISA) for seroconversion to avian HEV
antibodies as previously described (23, 25). All inoculated chickens were
necropsied at 8 weeks postinoculation (p.i.).
Determination of the infectivities of the genotype 3 swine HEV HVR deletion
mutants in SPF pigs. The in vivo transfection system developed in our previous
studies for testing the infectivities of swine HEV infectious cDNA clones and
mutants (26) was used to determine the infectivities of HVR deletion mutants in
pigs. Briefly, 18 6-week-old SPF pigs that were seronegative for HEV were
assigned to six groups of three each (groups A, B, C, D, E, and F). An ultra-
sound-guided technique was used to inoculate the pigs intrahepatically with
capped RNA transcripts from each of the mutants, as described previously (26).
The RNA transcripts were thawed and immediately injected into five different
sites in each liver with 200 l per injection site. The three pigs (no. 286, 296, and
608) in group A were each injected with 1 ml of the RNA transcripts from mutant
sHVRd1. Similarly, pigs 291, 295, and 613 in group B were each injected with
RNA transcripts from mutant sHVRd2; pigs 292, 604, and 606 (group C)
with RNA transcripts from sHVRd3; and pigs 288, 293, and 300 (group D) with
the RNA transcripts from mutant sHVRd4. The three pigs 603, 609, and 611 in
group F were each injected similarly with 1 ml of PBS buffer and served as
negative controls, and the three pigs 289, 294, and 612 in group E were intra-
hepatically injected with 1 ml of the RNA transcripts from the wild-type
pSHEV-3 infectious clone and served as positive controls (Fig. 4). Fecal samples
TABLE 1. Oligonucleotide primers used for construction of HVR
deletion mutants, as well as for PCR and sequencing, in this study
Primer ID Primer sequence (5 3 3)
For construction of avian HEV
HVR deletion mutants
AvF .................................................CCCGTTAACTGCGCACCACCGGCCG
Avf ..................................................CCCGTTAACGGCGGACCTGAGGTCA
AvR.................................................CGGGTTAACAAGCCAGTCGGCGGCA
Avr ..................................................CGGGTTAACCTGTGGCGGCAAGGGC
For construction of swine HEV
HVR-deletion mutants
SwF .................................................GACATCGCCGCTCGAGCCTCCCGC
CTAA
Swf1 ................................................ACATCTGGCTTTTCTCGCACTCGTCG
TCTC
Swf2 ................................................CCTGAGGCGGCCGCCCGTAAGCCAC
CAACA
Swf3 ................................................CTGCCCCACCCTACCTTACCCAGCTC
CATT
Swf4 ................................................ACATCTGGCTTTTCTTTACCCAGCTC
CATT
SwR.................................................GGGACCTGGTATATACCCGAGCCT
AGAA
Swr1 ................................................AGAAAAGCCAGATGTTGACCAAGTC
CGGGT
Swr2 ................................................GGCGGCCGCCTCAGGGGGGGAGAA
ATCGCT
Swr3 ................................................GGTAGGGTGGGGCAGCCCCGGGGC
AGCGGC
For construction of genotype 1
human HEV replicon
HVR-deletion mutants
HuF.................................................GGGAGCATGCTCAGAAGTTTATAAC
ACGCC
Huf1................................................TCGGAGGTTGATGCTCGCCGCCTGC
TCTTT
Huf2................................................CCCCCTGCACCGGATGGCGCTACCG
CCGGG
HuR ................................................GTACCTCTGGTAAAATGCATGACAG
AGCCC
Hur1................................................AGCATCAACCTCCGACCAAGTGCGG
GTGTA
Hur2................................................ATCCGGTGCAGGGGGGGGTAGAGG
GGCCGC
For sequencing of the HVR
region from viruses
recovered from pigs
and chickens
Av N1 .............................................TTACCATTGACTTTGAACGGCG
Av N3 .............................................GCTTGTGCATTGACGATTTCCC
Sw N1 .............................................CAGGTCAGGATTTCATCTAATGG
Av N2 .............................................CCGGGCTGATGGTCTCGATTAG
Av N4 .............................................CAATAGGTTACCCACGATGACG
Sw N2 .............................................GCCCTCACGCATAATGAACTCAG
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and sera were collected from all inoculated pigs at weekly intervals until they
were necropsied at 10 weeks p.i. Fecal and serum samples were tested by reverse
transcription (RT)-PCR (16, 36, 37, 59) for swine HEV RNA, and weekly serum
samples were also tested by ELISA for immunoglobulin G (IgG) antibodies to
swine HEV (16, 36).
Detection and sequencing of viruses recovered from experimentally infected
chickens and pigs. For the chicken study, fecal materials collected from inocu-
lated chickens at 3 weeks p.i. were tested by RT-PCR using the primers specific
for the avian HEV HVR. A nested PCR with external primers Av N1 and Av N2
and internal primers Av N3 and Av N4 (Table 1) were used to amplify the region
flanking the avian HEV HVR. Similarly, for the pig study, fecal materials col-
lected from the inoculated pigs at 4 weeks p.i. were tested by RT-PCR using the
primers specific for the genotype 3 swine HEV HVR. A One-step RT-PCR kit
(Invitrogen) was used to amplify the region flanking the swine HEV HVR using
the Sw N1 and Sw N2 primers (Table 1). The amplified PCR products from pigs
and chickens were purified with a GeneClean II kit and sequenced at the
Virginia Bioinformatic Institute. The sequences obtained from viruses recovered
from the infected chickens and pigs were compared with the sequences of the
original viruses used as the inocula.
RESULTS
The HVR is highly variable among HEV strains. Sequence
analyses confirmed the existence of an HVR in ORF1 of HEV
strains (Fig. 1). The intergenotypic amino acid sequence iden-
tity in the HVR among HEV isolates in different genotypes
differed by as much as 71%, whereas the intragenotypic amino
acid sequence identities among isolates within the same geno-
type differed by 31% among genotype 1 isolates, 41% among
genotype 3 isolates, 46% among genotype 4 isolates, and 30%
between the only two available avian HEV isolates (data not
shown). The variability of the HVR in genotype 2 is unknown,
since only one strain of genotype 2 HEV has been sequenced
to date. The predicted HVR for the HEV strains used in the
present study includes ORF1 aa 707 to 777 in genotype 1
human HEV (Sar55 strain) (Fig. 2), aa 707 to 790 in genotype
3 swine HEV (pSHEV-3 infectious clone) (Fig. 4), and aa 557
to 641 in avian HEV (Fig. 3). It was previously predicted, based
on sequence comparison of an apparently avirulent strain and
the prototype pathogenic strain of avian HEV, that the region
spanning aa 554 to 614 in ORF1 of avian HEV is hypervariable
(5). However, further sequence comparisons with mammalian
HEV strains revealed that the avian HEV genome downstream
of the originally predicted HVR at aa 615 to 641 also displayed
significant sequence variations. Therefore, we considered aa
557 to 641 the HVR of avian HEV for the purpose of
constructing avian HEV HVR deletion mutants in this study
(Fig. 3).
The HVR of genotype 1 human HEV is not required for virus
replication in vitro. We constructed two genotype 1 human
HEV HVR deletion mutants using a strain Sar55 HEV repli-
con expressing EGFP (Fig. 2). Huh7 cells were transfected
with capped RNA transcripts from a wild-type replicon and the
two mutants, hHVRd1 and hHVRd2. The transfected cells
were examined by fluorescence microscopy on days 4, 5, and 6
posttransfection for evidence of EGFP expression. EGFP flu-
orescence signal was detected in Huh7 cells transfected with
the wild-type Sar55 replicon, as well as in those transfected
with the mutant hHVRd2 replicon (Fig. 2), but not in the cells
transfected with the mutant hHVRd1 replicon. Fluorescence
was first detected on day 4, and the EGFP signal intensity
increased on days 5 and 6 posttransfection. Expression of
EGFP by the HVR deletion mutant hHVRd2 indicated that
the mutant is replication competent in Huh7 liver cells.
The HVR (aa 557 to 585 and aa 612 to 641) of avian HEV
tolerated deletions. To validate the dispensability of the HVR
for HEV replication observed in our in vitro study with the
genotype 1 human HEV replicon, we selected the genetically
distinct avian HEV for an in vivo study. Three avian HEV
HVR deletion mutants were generated using the avian HEV
infectious cDNA clone as the backbone (Fig. 3). The abilities
of the three avian HEV HVR deletion mutants to infect chick-
ens were tested by direct intrahepatic inoculation of SPF chick-
ens with capped RNA transcripts from each mutant. Serocon-
version to IgG anti-avian HEV was observed in all HVR
deletion mutant groups (A, B, and C), as well as in the positive
control group (D). In each group, however, only one or two
chickens out of the three that were inoculated seroconverted
(Fig. 3): only one chicken (no. 5361) in group A (aHVRd1)
seroconverted at 6 weeks p.i., chickens 5388 and 5353 of group
B (aHVRd2) seroconverted at 4 and 6 weeks p.i., and chicken
5354 of group C (aHVRd3) seroconverted at 5 weeks p.i. All
the chickens in the positive control group D seroconverted at
4 weeks p.i. The three negative control chickens (5352, 5358,
and 5369) remained seronegative through the experiment.
Avian HEV-specific RNA in feces was detected variably in
inoculated chickens (Table 2). In group A chickens (aHVRd1),
fecal virus shedding began at 3 weeks p.i. for chicken 5361.
Fecal virus shedding was delayed until 6 weeks p.i. in chicken
5357 and was not detected in chicken 5368. In group B chick-
ens (aHVRd2), fecal virus shedding began at 2 and 3 weeks p.i.
for chickens 5388 and 5353 but was undetectable in chicken
5372. None of the chickens in group C (aHVRd3) had detect-
able avian HEV RNA in the feces. Viremia could not be
detected in group A or C chickens (Table 1) and was transient
in chicken 5353 but lasted for 4 weeks in chicken 5388 of group
B. Transient viremia was detected in all chickens of positive
control group D.
The HVR of genotype 3 swine HEV is not required for in vivo
infectivity. To further verify the results from the avian HEV
FIG. 3. (A) Schematic diagram showing the HVR (aa 557 to 641) in ORF1 of avian HEV, along with putative functional domains: MET,
methyltransferase; P, papain-like cysteine protease; H, HVR; HEL, helicase; and RDRP, RNA-dependent RNA polymerase. The amino acid
sequence of each HVR deletion mutant is aligned with that of the wild-type strain of avian HEV to show the relative positions of the in-frame
amino acid deletions: mutants aHVRd1 (aa 557 to 585), aHVRd2 (aa 612 to 641), and aHVRd3 (aa 557 to 641). (B) Seroconversion to IgG
anti-HEV in chickens inoculated with capped RNA transcripts from the wild-type avian HEV infectious clone and its derived HVR deletion
mutants. IgG anti-HEV was plotted as the ELISA optical density (OD) (A405), and the ELISA cutoff value was 0.30. Chickens 5357, 5361, and 5368
were each inoculated with RNA transcripts from HVR deletion mutant aHVRd1 (group A); chickens 5353, 5372, and 5388 with RNA transcripts
from mutant aHVRd2 (group B); and chickens 5354, 5355, and 5385 with RNA transcripts from mutant sHVRd3 (group C). Chickens 5362, 5367,
and 5374 (group D) were each inoculated with RNA transcripts from the wild-type avian HEV infectious cDNA clone as positive controls, and
chickens 5352, 5358, and 5369 (group E) were intrahepatically inoculated with PBS buffer as negative controls.
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chicken study and the in vitro genotype 1 HEV replicon study,
we subsequently constructed four swine HEV mutants using
the genotype 3 swine HEV infectious cDNA clone as the
backbone (Fig. 4). The abilities of the four genotype 3 swine
HEV mutants to infect pigs were tested by direct intrahepatic
inoculation of SPF pigs with capped RNA transcripts from
each mutant. Since the intrahepatic inoculation of RNA tran-
scripts of avian HEV HVR mutants in chickens was a blind
percutaneous procedure (24), some chickens may not have
received, or received much less, inocula in the livers. To ensure
that all animals received equal amounts of RNA inocula, in the
pig study with the genotype 3 HEV HVR deletion mutants, we
used an ultrasound-guided technique for the intrahepatic in-
jection to make sure that the RNA inocula were injected di-
rectly into the liver. All the pigs in groups A, B, C, and D,
which were injected with capped RNA transcripts from respec-
tive HVR deletion mutants, seroconverted to IgG anti-HEV,
indicating that active swine HEV infections had occurred in
the inoculated pigs (Fig. 4). All the pigs in group B (sHVRd 2),
group C (sHVRd 3), and group D (sHVRd 4) seroconverted at
about 3 to 5 weeks p.i. The three pigs in group A (sHVRd 1)
had a delayed seroconversion at 6 to 7 weeks p.i. The positive
control pigs in group E (pSHEV-3) seroconverted at 3 to 4
weeks p.i. The three negative control pigs in group F remained
seronegative throughout the course of study (Fig. 4).
Fecal virus shedding occurred variably in pigs of groups B,
C, and D (Table 3). There was no fecal virus shedding in group
A pigs. Delayed fecal virus shedding occurred in pigs 291 and
295 of group B at 9 to 10 weeks p.i., while there was no fecal
virus shedding in pig 613. Fecal virus shedding occurred as
early as 1 week p.i. in group C pigs and at 2 weeks p.i. in group
D pigs and lasted for 5 to 8 weeks. Viremia was not detected
in group A or B pigs (Table 3). Viremia was detected only in
pig 604 of group C at 3 and 6 weeks p.i. and only in pig 288 of
group D at 5 weeks p.i. (Table 3).
Viruses recovered from infected chickens and pigs retained
their respective deletions in the HVR. Viruses recovered from
the feces of chicken no. 5361 from group A and chicken no.
5388 from group B at 3 weeks p.i. were sequenced to confirm
the presence of deletions in the HVR. Sequence analyses re-
vealed that the recovered virus from chicken no. 5361 retained
its nt 1693 to 1779 deletion and the virus recovered from
chicken no. 5388 also retained its nt 1858 to 1947 deletion.
Similarly, we also amplified and sequenced the HVRs of
FIG. 4. (A) Schematic diagram showing the HVR (aa 707 to 790) in ORF1 of the genotype 3 swine HEV. MET, methyltransferase; P,
papain-like cysteine protease; Y, Y domain; H, HVR; X, X domain; HEL, helicase; and RDRP, RNA-dependent RNA polymerase. The amino
acid sequence of each HVR deletion mutant is aligned with that of the wild-type strain of the genotype 3 swine HEV to show the relative positions
of the in-frame amino acid deletions: mutants sHVRd1 (aa 712 to 790), sHVRd2 (aa 722 to 781), sHVRd3 (aa 735 to 765), and sHVRd4 (aa 712
to 765). (B) Seroconversion to IgG anti-HEV in pigs inoculated with capped RNA transcripts from the wild-type swine HEV infectious clone and
its derived HVR deletion mutants. IgG anti-HEV was plotted as the ELISA optical density (OD) (A405), and the ELISA cutoff value was 0.30. Pigs
286, 296, and 608 were each inoculated with capped RNA transcripts from HVR deletion mutant sHVRd1 (group A); pigs 291, 295, and 613 with
RNA transcripts from mutant sHVRd2 (group B); pigs 292, 604, and 606 with RNA transcripts from mutant sHVRd3 (group C); pigs 288, 293,
and 300 with RNA transcripts from mutant sHVRd4 (group D); and pigs 289, 294, and 612 with RNA transcripts from wild-type genotype 3 swine
HEV infectious clone pSHEV-3 (group E). Pigs 603, 609, and 611 were intrahepatically inoculated with PBS buffer as negative controls (group F).
TABLE 2. Detection of avian HEV RNAa
Group Chicken no.
Result (fecal/serum) at week p.i.:
0 1 2 3 4 5 6 7 8
A (aHVRd1) 5357 / / / / / / / / /
5361 / / / / / / / / /
5368 / / / / / / / / /
B (aHVRd2) 5353 / / / / / / / / /
5372 / / / / / / / / /
5388 / / / / / / / / /
C (aHVRd3) 5354 / / / / / / / / /
5355 / / / / / / / / /
5385 / / / / / / / / /
D (wild-type clone)
(positive control
group)
5362 / / / / / / / / /
5367 / /  / / / / / /
5374 / / / / / / / / /
E (negative control
group)
5352 / / / / / / / / /
5358 / / / / / / / / /
5369 / / / / / / / / /
a Positive () or negative () samples at the indicated week p.i. in SPF chickens intrahepatically inoculated with capped RNA transcripts of avian HEV HVR
deletion mutants, as well as the wild-type avian HEV infectious clone.
VOL. 83, 2009 ROLE OF ORF1 HYPERVARIABLE REGION IN HEV REPLICATION 391
the rescued viruses from selected pigs inoculated with the
genotype 3 HVR deletion mutants. The introduced dele-
tions nt 2190 to 2369 for group B pigs, nt 2229 to 2321 for
group C pigs, and nt 2160 to 2321 for group D pigs were
retained intact in the viruses recovered from the fecal sam-
ples collected at 4 weeks p.i.
DISCUSSION
The objective of this study was to assess the role of the HVR
in ORF1 of HEV in virus replication and/or pathogenesis.
Sequence analysis of known HEV strains revealed an HVR
with a high degree of variability at both amino acid and
nucleotide sequence levels. This region overlaps the proline-
rich hinge region of ORF1 (25, 32, 44, 53). It is known that
inherent structural constraints can influence the vulnerabil-
ity of genomic segments to replication errors during virus
infection, resulting in the accumulation of mutations for ge-
netic diversity (13). The size differences in HEV genomes from
different genotypes are confined mainly to the HVR of ORF1,
which spanned 105 aa as originally proposed (31, 53). As the
sequences of additional HEV isolates were published, it be-
came clear that the first 35 aa in the originally described HVR
among HEV strains (53) is not hypervariable. Thus, the true
HVR is 70 to 72 aa for genotype 1 HEV, 68 aa for genotype 2
HEV, 80 to 86 aa for genotype 3 HEV, 84 aa for all genotype
4 HEVs, and 84 aa for avian HEV (based on the corresponding
region in mammalian HEVs). HEV genomes exhibited in-
creased divergence in the HVR encompassing aa 707 to 777 for
genotype 1 human HEV, aa 707 to 790 for genotype 3 swine
HEV, and aa 557 to 641 for avian HEV. Extensive sequence
variations observed among isolates in the four major genotypes
of mammalian HEV and avian HEV, as well as within each
genotype, suggested that the HVR may not be necessary for
virus replication. It has been shown that a 507-nt deletion in a
variable nonstructural region of rubella virus, a virus distantly
related to HEV, is not required for virus replication (56).
Therefore, we hypothesize that the HVR of HEV is not re-
quired for virus infectivity.
To test our hypothesis, we first constructed two genotype 1
human HEV HVR deletion mutants using the EGFP-express-
ing Sar55 HEV replicon as the backbone: mutants hHVRd1
(aa 711 to 777 deleted) and hHVRd2 (aa 747 to 761 deleted).
The wild-type Sar55 EGFP replicon, which was constructed in
our laboratory (Huang and Meng, unpublished), was shown to
be replication competent and expressed EGFP when trans-
fected into Huh7 liver cells. The two HVR deletion mutants
(hHVRd1 and hHVRd2) were tested for viability and replica-
tion competency in Huh7 cells. EGFP fluorescence signal was
detected in Huh7 cells transfected with the mutant hHVRd2,
as well as with the wild-type Sar55 replicon, but not in the cells
transfected with the HVR deletion mutant hHVRd1. The re-
sults from this experiment showed that the mutant hHVRd2
with partial HVR deletion is viable, and thus, the HVR is
dispensable for virus replication in vitro. The absence of EGFP
expression for mutant hHVRd1, which contains a deletion of
the nearly complete HVR, suggested that this mutant is not
replication competent. Therefore, it is likely that the end se-
quences of the HVR for genotype 1 human HEV may be
important for virus viability. Nevertheless, partial deletion of
HVR sequence in the middle region, as revealed by mutant
hHVRd2 (Fig. 2), apparently does not affect the replication
ability of the genotype 1 human HEV in vitro.
To further confirm our results from the in vitro study with
genotype 1 human HEV replicon mutants, we utilized a genet-
TABLE 3. Detection of HEV RNAa
Group Pig no.
Result (fecal/serum) at week p.i.:
0 1 2 3 4 5 6 7 8 9 10
A (sHVRd1) 286 / / / / / / / / / / /
296 / / / / / / / / / / /
608 / / / / / / / / / / /
B (sHVRd2) 291 / / / / / / / / / / /
295 / / / / / / / / / / /
613 / / / / / / / / / / /
C (sHVRd3) 292 / / / / / / / / / / //
604 / / / / / / / / / / /
606 / / / / / / / / / / /
D (sHVRd4) 288 / / / / / / / / / / /
293 / / / / / / / / / / /
300 / / / / / / / / / / /
E (wild-type clone) 289 / / / / / / / / / / /
(Positive control 294 / / / / / / / / / / /
group) 612 / / / / / / / / / / /
F (negative control 603 / / / / / / / / / / /
group) 609 / / / / / / / / / / /
611 / / / / / / / / / / /
a In samples that were positive () or negative () at the indicated week p.i. in SPF chickens intrahepatically inoculated with capped RNA transcripts of swine HEV
HVR deletion mutants, as well as the wild-type infectious clone.
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ically distinct chicken strain of HEV (avian HEV); we con-
structed three avian HEV mutants with various deletions in the
HVR and tested the mutants for the ability to infect chickens.
Based on the amino acid sequence alignment of avian HEV
with other mammalian HEV strains, we found that the region
spanning aa 557 to 641 in avian HEV is highly divergent and
thus termed it the HVR for avian HEV. A total of three avian
HEV HVR deletion mutants with various lengths were con-
structed: aHVRd1, with a partial deletion in the 5 end of the
HVR; aHVRd2, with a partial deletion in the 3 end of the
HVR; and aHVRd3, with the deletion of the nearly complete
HVR (Fig. 3). The infectivities of the three avian HEV mu-
tants were tested in chickens by intrahepatically inoculating the
RNA transcripts from each mutant into the livers of live chick-
ens. The kinetics of virus replication appears to be different in
chickens infected with different mutants and wild-type avian
HEV (Fig. 3). Although seroconversion was observed in chick-
ens inoculated with all three mutants, only one or two out of
the three inoculated chickens had seroconverted (Fig. 3). Since
the percutaneous intrahepatic-injection procedure used in this
study to inoculate RNA transcripts into chicken livers is a blind
procedure (24), it was quite possible that the RNA transcripts
were not injected into the livers of some chickens or that only
a small amount was injected (24). This may explain why not all
inoculated chickens seroconverted to avian HEV antibodies.
Fecal virus shedding and viremia were detected only in mu-
tants aHVRd1 and aHVRd2. Deletions in the HVR may in-
fluence the replicative competence of the virus and thus may
attenuate avian HEV. Therefore, attenuation of HVR deletion
mutants to replicate at lower levels could explain why viral
RNA was not detected in sera from group A chickens
(aHVRd1) or in feces and sera of group C chickens (aHVRd3).
Clearly, future studies are warranted to explore any potential
role of the HVR in virus attenuation, which is beyond the
scope of this study. The results from this avian HEV and
chicken study indicated that the HVR of avian HEV is not
essential for virus infectivity in vivo, although the avian HEV
mutant with complete HVR deletion displayed an apparent
attenuation phenotype.
In order to definitively verify our results from the avian HEV
and chicken study, as well as from the in vitro genotype 1 HEV
replicon mutant study, we subsequently constructed four ge-
notype 3 swine HEV mutants with various HVR deletions:
sHVRd1, with the deletion of the nearly complete HVR se-
quence; sHVRd2 and sHVRd3, with partial deletions of HVR
sequences in the middle region; and sHVRd4, with a deletion
of partial HVR sequence at the 5 end (Fig. 4). The infectiv-
ities of these four mutants were tested in pigs by intrahepatic
inoculation of capped RNA transcripts from each mutant via
an ultrasound-guided inoculation procedure. Similar to our
observations in the chicken study, we found that mutants sH-
VRd2, sHVRd3, and sHVRd4, with partial deletions of the HVR
sequences at the 5 end and in the middle region, are viable and
infectious in pigs. Seroconversion was observed for all HVR de-
letion mutants; however, there was a delayed seroconversion with
no detectable viral RNA in feces or sera for pigs inoculated with
mutant sHVRd1, which contains the nearly complete HVR
deletion, an indication of attenuation for the sHVRd1 virus.
Viral RNA was detected much later during infection, at 9
weeks p.i., in pigs (no. 291 and no. 295) infected with mutant
sHVRd2, which contains a larger sequence deletion of the
HVR than mutants sHVRd3 and sHVRd4. Fecal virus shed-
ding was detected at 1 and 2 weeks p.i. in pigs inoculated with
mutants sHVRd3 and sHVRd4 and lasted for 5 to 8 weeks.
These results suggest that mutants sHVRd1 and sHVRd2, with
larger sequence deletions of the HVR, may be attenuated to
replicate at lower levels, and it appears that the lengths of
HVR deletions may affect the level of virus replication and
attenuation. Again, additional studies to explore the role of the
HVR in HEV attenuation, which is not within the scope of this
study, will provide more insights into the role of the HVR in
the biology and pathogenesis of HEV.
The patterns of viremia and fecal virus shedding in experi-
mentally infected pigs and chickens (Tables 2 and 3) are some-
what different from that observed in HEV-infected humans. In
humans, viremia usually precedes fecal virus shedding,
whereas in the pig and chicken studies fecal virus shedding was
detected prior to viremia, which is consistent with our previous
animal studies (5, 16). It is believed that tissues in the gastro-
intestinal tract are the initial sites of swine HEV and avian
HEV replication, and thus, the virus is excreted to the feces
before entering the bloodstream. In fact, it has recently been
demonstrated that after oral injection or intravenous injection,
swine HEV and avian HEV first replicate in various gastroin-
testinal tissues in chickens and pigs before reaching the target
organ, the liver, via the bloodstream (6, 59), and this may
explain why fecal virus shedding precedes viremia in HEV-
infected pigs and chickens.
Since ORF1 contains domains essential for HEV replica-
tion, proper folding of the encoded polyprotein is essential for
its role in virus replication either individually or by interacting
with host alleles. The results from our in vitro, as well as in
vivo, animal studies showed that the deletions in the HVR did
not influence the viability of the virus, and thus, the polypro-
tein encoded by ORF1 appears to be properly folded in viable
mutants. The HVR, aa 747 to 761 of genotype 1 human HEV,
aa 557 to 585 and 612 to 641 of avian HEV, and aa 712 to 765
of genotype 3 swine HEV, apparently has no major effect on
the host-mediated processing of the polyprotein, as the mutant
viruses are viable and infectious in animals. Since unneeded
sequences in virus genomes normally are lost rapidly during in
vivo replication, it is possible that the HVR, although not
essential for virus infectivity, may play a biological role in HEV
pathogenesis. In fact, the results from the animal studies with
limited numbers of pigs and chickens suggested that deletions
of a larger or nearly complete HVR from the HEV genome
apparently attenuated the virus. Therefore, additional studies
with larger numbers of animals are warranted to fully evaluate
the biological role of HVR in HEV replication and pathogen-
esis.
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